Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced on July 1, 2021, the approval of "inducement" grants to 42 new employees by its Board of Directors’ Compensation Committee. These grants, totaling up to 157,000 restricted stock units, are outside of the company's stockholder-approved equity incentive plans and vest annually over four years. Arrowhead develops RNAi-based therapeutics targeting intractable diseases by silencing specific genes, aiming for effective gene expression inhibition.
- Approval of inducement grants to 42 new employees, indicating company growth and talent acquisition.
- Total of 157,000 restricted stock units granted, reflecting commitment to incentivizing new hires.
- None.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 1, 2021, the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to 42 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 157,000 restricted stock units. The grants are outside the Company’s stockholder-approved equity incentive plans and vest annually over four years.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company’s email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.
Source: Arrowhead Pharmaceuticals, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005350/en/
FAQ
What did Arrowhead Pharmaceuticals announce on July 1, 2021?
How many restricted stock units were granted to new employees at Arrowhead Pharmaceuticals?
Are the stock grants at Arrowhead Pharmaceuticals part of an approved equity incentive plan?
How do the restricted stock units at Arrowhead Pharmaceuticals vest?
